Help the refugees

If you move around the world by choice, consider helping those forced from their homes by conflict. Donate to the UN Refugee Agency today.

Back

ENGINEER IN IMMUNO-ONCOLOGY / U932 – LANTZ TEAM / PARIS

Visit website

Location: INSERM U932, Institut Curie, Paris, France

Date posted: 15 July 2022

Starting date: as early as september

Duration: 18 months to 3 years

The research group of Dr. Olivier Lantz (Inserm U932, Paris, France) is seeking an immunology and oncology engineer. The candidate will be dedicated to identifiy and validate novel tumor-specific neoantigens shared between cancer patients.

Context

Institut Curie is one of the largest European institutions for cancer and biomedical research with strong interdisciplinary traditions. It is located in the center of Paris in France, in a both cultural and scientific rich environment. The site has active seminar program and hosts regular training sessions in molecular and cellular biology. The project will be developed in Center of Cancer Immunotherapy headed by Dr S. Amigorena and the Clinic Immunology Laboratory headed by Dr O. Lantz. The Immunology Department headed by Dr. AM Lennon includes 8 independent research teams in the fields of basic and applied immunology, working in a very collaborative and international environment. Candidate will work under the supervision of Dr. Olivier Lantz. The aim of the team is to characterize the biology of T cells, their interaction with other cells of the immune system, and their role in cancer, in both humans and through mice models. The open position is in line with recent developments at the interface between Immunology and Cancer (Bigot et al. Cancer Discovery 2021). More information: www.curie.fr and http://u932.curie.fr/ .

Project

The project aim at identifying tumor-specific neo-Ag derived from RNA processing or expression in human cancers. The in silico predicted neo-Ag will be further evaluated using immune-peptidomic. After definition of the most promising epitopes, the spontaneous response they induce in patients and their putative immunogenicity will be determined. The induction of an immune response in PBMCs from healthy donor or cancer patients and/or recognition by specific CD8 T cell clones will be assessed. The candidate will work in close collaboration on this research program with a postdoctoral fellow and a research engineer.

Profile

  • Master 2 in immunology, molecular and cellular biology, or biothechnology
  • Some knowledge in human immunology, oncology and immunotherapy will be highly appreciated
  • Some expertise in flow cytometry will be highly appreciated
  • Scientific rigor and excellent analytical and synthetic capabilities
  • Team spirit and dynamic personality with passion for innovation and problem-solving

Bigot J, Lalanne AI, Lucibello F,…Lantz O. Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes. Cancer Discov. 2021 Aug;11(8):1938-1951. doi:10.1158/2159-8290.CD-20-0555

Apply now